Archives: Agenda

Successful biotech development is rarely about choosing between one expert or a team. It is about having access to the right expertise at the right time, supported by a model that can scale as development needs evolve.

In this session we will explore:

• The advantages and limitations of relying on a single trusted consultant versus a multidisciplinary team supporting development from IND through commercialization.
• How integrated consulting teams can bring together regulatory, clinical, CMC, biostatistics, medical writing, and market access capabilities to address evolving development needs.
• Strategies for managing increasing complexity as programs progress across functions, stakeholders, and global regions.
• How scalable consulting models can reduce execution risk through coordinated planning, quality oversight, business continuity, and access to specialized support.

The value of coordinated global perspectives across FDA, EMA, PMDA, NMPA, MHRA, and other regulatory agencies while maximizing limited internal resources.

Biotech companies often operate with lean teams and limited resources yet face the same complexities as larger pharma. This session will explore how smaller organisations can maximise internal capabilities, leverage cross-functional talent, and build efficient operating models to successfully deliver clinical trials.

• Making the most of lean teams: prioritisation and resource allocation strategies
• Leveraging cross-functional talent and transferable skillsets across departments
• Building agile operating models to increase efficiency and speed
• When to outsource vs keep capabilities in-house
• Empowering individuals to take on broader roles and responsibilities
• Creating a culture of collaboration and flexibility to drive delivery

For biotech and emerging biopharma companies, every development decision carries significant implications for timelines, funding milestones, and investor confidence. As pressure mounts to advance programs faster, the most successful organizations are using predictive analytics, integrated development planning, and data-driven decision-making to de-risk clinical development and accelerate execution across the entire development lifecycle.

Join this session to learn how biotech sponsors can reduce uncertainty from first-in-human studies through pivotal trials by reducing delays between phases, increasing cross-functional coordination, and improving operational execution to bring therapies to patients faster.

Key Discussion Points:

• Accelerating transitions between Phase I, II, and III studies
• Reducing operational “white space” between development milestones
• Increasing parallelization of clinical, regulatory, and operational workstreams
• Improving enrollment forecasting and predictability
• Driving efficiency and speed across the end-to-end development lifecycle

• Navigating traditional and niche CRO models as an emerging biotech
• Understanding the key differences between big pharma and biotech approaches to clinical trial execution and outsourcing strategy
• Examining how niche and specialist vendors are addressing sponsor pain points with more tailored, flexible solutions
• Identifying how sponsors and providers can better align expectations, communication models, and operational support for successful partnerships

When managing complex cardiovascular, CNS, and oncology trials, clinical sites often navigate siloed applications to consolidate patient data. This operational burden delays the review of critical patient information, including eCOA completion, sensor data, and consent status, making it harder to identify which patients are falling behind or where immediate action is needed.

In this valuable session, we’ll share a practical roadmap for elevating patient care and reducing site burden. Join us to learn how to optimize clinical workflows, reduce data entry lag, and balance technology needs with real-world site capacity. You’ll discover strategies for using patient adherence data to drive a more efficient and successful trial experience.

We’ll explore:

• How to help site staff spend less time chasing data and more time focused on high-value patient interactions and outcomes
• Leverage AI and real-time data to gain a holistic view of patient activity, moving from reactive monitoring to proactive care
• Ways to pinpoint and resolve common trial hurdles with flexible options that reduce burden for both patients and sites
• Best practices to identify and act on early warning signs of patient disengagement to help protect trial timelines and data quality

Opening Question

“If your AI is trained on incomplete data, who is it really working for – and who is it leaving behind?” 

Key Focus Areas

• How reliance on historical datasets creates systemic gaps, leaving underrepresented groups without sufficient data to ensure accurate AI outputs
• Exploring the real-world impact of misrepresentation through live audience polling and scenario-based discussions
• Challenging assumptions: where do we overtrust AI, and how aware are organisations of its limitations?
• Practical steps to improve outcomes, including how to identify bias and push for more inclusive, representative data

Format

This session will be highly interactive, using live polling, audience Q&A, and scenario-led discussion to test perceptions and uncover blind spots. Attendees will respond to real-world scenarios, compare perspectives across the room, and collectively explore how bias and data gaps influence decision-making in practice.